News

Sitari has been developing a novel treatment for celiac disease and was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI

The deal includes a fixed consideration of $175m (£141m), comprised of an upfront payment of $135 (£109m) and a long-term note for $40m (£32m), as well as contingent

GVOKE is a ready-to-use, room-temperature stable liquid glucagon product, which can be administered to the patient using a prefilled syringe or auto-injector. The liquid glucagon product will be

“We’re pleased that the FDA has granted this designation for sotatercept,” said Janethe de Oliveira Pena, MD, PhD, Vice President, Pulmonary Medical Research at Acceleron. “In preclinical studies,

The FDA grants Priority Review designation to applications for medicines that have the potential to provide significant improvements in the treatment of serious conditions. Priority Review is associated

The ASPIRE I and II trials evaluated the efficacy and safety of esketamine nasal spray in 465 patients with the moderate-to-severe major depressive disorder who have active suicidal

Imfinzi, along with four cycles of standard-of-care (SoC) chemotherapy, showed a statistically-significant and clinically-meaningful improvement in OS against SoC including up to six cycles of chemotherapy and optional

Ofev has been indicated for slowing the rate of decline in pulmonary function in adult patients with SSc-ILD, which makes it the first FDA-approved treatment for the rare

The funding was led by the JDRF T1D Fund, Sanofi Ventures, and the VTC Innovation and VTC Seed Fund, with participation from the Maryland Momentum Fund, the University